Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
HEC Forum : an Interdisciplinary Journal on Hospitals' Ethical and Legal Issues
|
February 12, 2026
Navigating Ethical Challenges in CAR-T Treatment
Elise R A Pennings, Anne M Spanjaart, Anne Ruth Schaaphok, et al.
Blood Cancer Journal
|
January 4, 2024
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Elise R A Pennings, Müjde Durmaz, Otto Visser, et al.
Hematological Oncology
|
June 29, 2023
Cellular therapy in lymphoma
Anna Sureda, Pieternella J Lugtenburg, Marie José Kersten, et al.
Cancers
|
November 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
Janneke W de Boer, Kylie Keijzer, Elise R A Pennings, et al.
Hemasphere
|
March 9, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies
Elise R A Pennings, Frederick W Thielen, Florence Broussais, et al.
Blood Advances
|
August 28, 2023
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
Janneke W de Boer, Elise R A Pennings, Ankie Kleinjan, et al.
JCO Oncology Practice
|
December 12, 2022
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
Anne M Spanjaart, Elise R A Pennings, Milan Kos, et al.
Cancers
|
September 9, 2023
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
Anne M Spanjaart, Elise R A Pennings, Pim G N J Mutsaers, et al.
Blood Advances
|
September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe
Elise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
HEC Forum : an Interdisciplinary Journal on Hospitals' Ethical and Legal Issues
|
February 12, 2026
Navigating Ethical Challenges in CAR-T Treatment
Elise R A Pennings, Anne M Spanjaart, Anne Ruth Schaaphok, et al.
Blood Cancer Journal
|
January 4, 2024
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Elise R A Pennings, Müjde Durmaz, Otto Visser, et al.
Hematological Oncology
|
June 29, 2023
Cellular therapy in lymphoma
Anna Sureda, Pieternella J Lugtenburg, Marie José Kersten, et al.
Cancers
|
November 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
Janneke W de Boer, Kylie Keijzer, Elise R A Pennings, et al.
Hemasphere
|
March 9, 2026
The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies
Elise R A Pennings, Frederick W Thielen, Florence Broussais, et al.
Blood Advances
|
August 28, 2023
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
Janneke W de Boer, Elise R A Pennings, Ankie Kleinjan, et al.
JCO Oncology Practice
|
December 12, 2022
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
Anne M Spanjaart, Elise R A Pennings, Milan Kos, et al.
Cancers
|
September 9, 2023
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
Anne M Spanjaart, Elise R A Pennings, Pim G N J Mutsaers, et al.
Blood Advances
|
September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe
Elise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Page
of 1